Adult SMA Research and Clinical Hub

The Adult SMA REACH study is a really important project that aims to understand more about Spinal Muscular Atrophy (SMA) in adults in the UK. SMA is a genetic condition that affects the nerves that control muscle movement, and it can vary a lot in how it affects people. Over the past few years, there have been exciting developments in treatments for SMA, which have made a big difference for many patients. However, we still need to learn a lot about how these treatments work in the long run and how they affect adults with SMA. This study is all about gathering that crucial information.

This study isn't testing a new medication; instead, it's collecting information about the treatments and care adults with SMA are already receiving. This includes treatments like Nusinersen and Risdiplam, which are currently available in the UK through special programmes. By collecting this information, researchers can get a clearer picture of how these treatments are impacting daily life and health over time. This helps doctors make better decisions about care and helps shape future research into SMA.

The Adult SMA REACH study builds on the success of a similar study for children with SMA. It works with other expert groups and registries in the UK and internationally to make sure the information collected is useful and consistent. The study is run by The Newcastle upon Tyne Hospitals NHS Foundation Trust and supported by funding from Biogen and Roche. The overall aim is to improve the lives of people with SMA by learning more about the condition and the effects of available treatments.